| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
47,934,000 |
| Market
Cap: |
1.41(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$9.56 - $31 |
|
| Level
I Sector: |
N/A |
| Level
II Sector: |
N/A |
| Level
III Sector: |
N/A |
|
Member Indexes:
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Homology Medicines is a genetic medicines company. Co.'s proprietary platform is designed to utilize its human hematopoietic stem cell derived adeno-associated virus vectors to deliver single administration genetic medicines in vivo either through its gene therapy, Co.'s nuclease-free gene editing modality, or Co.'s gene therapy to express antibodies platform. Co.'s clinical programs include: HMI-102, an investigational gene therapy candidate in clinical development for the treatment of adult patients with phenylketonuria; as well as HMI-103, an investigational gene editing candidate in clinical development for the treatment of patients with PKU.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
343 |
22,368 |
25,768 |
60,242 |
| Total Sell Value |
$8,303 |
$20,843 |
$25,214 |
$73,768 |
| Total People Sold |
2 |
3 |
5 |
7 |
| Total Sell Transactions |
2 |
5 |
8 |
14 |
| End Date |
2024-02-22 |
2023-11-21 |
2023-05-23 |
2022-05-23 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Jordan Julie |
Chief Medical OfficerOfficer |
• – – |
2023-03-07 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
2,519 |
|
-36% |
|
| Alloway Paul |
See Remarks |
• – – |
2023-03-02 |
4 |
AS |
$1.45 |
$15,863 |
D/D |
(10,965) |
16,706 |
|
-37% |
|
| Alloway Paul |
See Remarks |
• – – |
2023-01-09 |
4 |
AS |
$1.39 |
$4,296 |
D/D |
(3,090) |
20,103 |
|
-37% |
|
| Blum Michael Lee |
Chief Commercial Officer |
• – – |
2023-01-09 |
4 |
AS |
$1.39 |
$3,412 |
D/D |
(2,454) |
13,538 |
|
-37% |
|
| Smith W Bradford |
See Remarks |
• – – |
2023-01-09 |
4 |
AS |
$1.39 |
$5,188 |
D/D |
(3,729) |
14,219 |
|
-37% |
|
| Seymour Albert |
See Remarks |
• • – |
2023-01-09 |
4 |
AS |
$1.39 |
$5,033 |
D/D |
(3,620) |
143,166 |
|
-37% |
|
| Tzianabos Arthur |
Director |
– • – |
2023-01-09 |
4 |
AS |
$1.39 |
$14,762 |
D/D |
(10,616) |
108,395 |
|
-37% |
|
| Smith W Bradford |
See Remarks |
• – – |
2023-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,530 |
17,948 |
|
- |
|
| Alloway Paul |
See Remarks |
• – – |
2023-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
9,570 |
23,193 |
|
- |
|
| Seymour Albert |
See Remarks |
• • – |
2023-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
11,220 |
146,786 |
|
- |
|
| Tzianabos Arthur |
Director |
– • – |
2023-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
33,000 |
119,011 |
|
- |
|
| Blum Michael Lee |
Chief Commercial Officer |
• – – |
2023-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
7,590 |
15,992 |
|
- |
|
| Blum Michael Lee |
Chief Commercial OfficerOffice |
• – – |
2022-03-02 |
3/A |
IO |
$0.00 |
$0 |
D/D |
0 |
3,280 |
|
- |
|
| Alloway Paul |
See RemarksOfficer |
• – – |
2022-03-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
10,226 |
|
-40% |
|
| Blum Michael Lee |
Chief Commercial OfficerOffice |
• – – |
2022-03-02 |
3 |
IO |
$0.00 |
$0 |
D/D |
0 |
6,780 |
|
-40% |
|
| Seymour Albert |
Chief Scientific Officer |
• – – |
2022-01-05 |
4 |
AS |
$3.78 |
$6,279 |
D/D |
(1,661) |
131,646 |
|
-60% |
|
| Kelly Timothy P |
Chief Operating Officer |
• – – |
2022-01-05 |
4 |
AS |
$3.78 |
$5,315 |
D/D |
(1,406) |
2,224 |
|
-60% |
|
| Cohn Gabriel |
Chief Medical Officer |
• – – |
2022-01-05 |
4 |
AS |
$3.78 |
$6,279 |
D/D |
(1,661) |
2,629 |
|
-60% |
|
| Smith W Bradford |
CFO & Treasurer |
• – – |
2022-01-05 |
4 |
AS |
$3.78 |
$8,248 |
D/D |
(2,182) |
4,418 |
|
-60% |
|
| Tzianabos Arthur |
President & CEO |
• • – |
2022-01-05 |
4 |
AS |
$3.78 |
$20,239 |
D/D |
(5,354) |
86,011 |
|
-60% |
|
| Seymour Albert |
Chief Scientific Officer |
• – – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,290 |
133,307 |
|
- |
|
| Kelly Timothy P |
Chief Operating Officer |
• – – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
3,630 |
3,630 |
|
- |
|
| Cohn Gabriel |
Chief Medical Officer |
• – – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
4,290 |
4,290 |
|
- |
|
| Smith W Bradford |
CFO & Treasurer |
• – – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
6,600 |
6,600 |
|
- |
|
| Tzianabos Arthur |
President & CEO |
• • – |
2022-01-01 |
4 |
OE |
$0.00 |
$0 |
D/D |
13,860 |
91,365 |
|
- |
|
148 Records found
|
|
Page 2 of 6 |
|
|
0.36 (1.21%) 
